Golimumab for the treatment of psoriatic arthritis

NICE technology appraisal guidance [TA220] Published date:

NICE recommends golimumab as a possible treatment for people with psoriatic arthritis in the same circumstances as other drugs for this condition (see 'Who can have golimumab?*' below).

Who can have golimumab?*

You should be able to have golimumab if you have three tender and three swollen joints and you have already tried at least two disease-modifying drugs (DMARDs), given on their own or together, but they haven't worked.

Only people whose psoriatic arthritis improves enough by 12 weeks should be able to carry on with treatment.

When assessing whether your psoriatic arthritis has improved, healthcare professionals should take into account any disabilities or difficulties in communicating you may have.

*The circumstances described in this section are the same circumstances in which NICE recommends etanercept, infliximab and adalimumab (see www.nice.org.uk/guidance/TA199).

Get involved